News
Modular Medical Announces Licensing and Partnership Agreement With Nudge BG
-Modular Medical will collaborate with Nudge BG to bring to market an adaptive full closed loop Automated Insulin Delivery system that does not require mealtime announcements-Effort will be led be Nudge BG founder and noted AID expert, Lane Desborough SAN DIEGO, CA /...
Modular Medical Announces Conference Call to Provide Business Update
SAN DIEGO, CA / December 3, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (Nasdaq:MODD), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly...
Modular Medical Announces Pricing of $8.2 Million Public Offering
SAN DIEGO, CA / November 21, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly...
Modular Medical Announces Proposed Public Offering
SAN DIEGO, CA / November 21, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable...
Modular Medical Proudly Sponsors the Inaugural Achieving Diabetes Equity in Practice Today (ADEPT) Conference
SAN DIEGO, CA / November 11, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly...
Registration Is Now Open For Tribe Public’s Webinar Event “Tailoring GLP-1 Weight Loss Treatments: Innovative Approaches To Personalized Dosing” Featuring Modular Medical CEO On Monday, November 11, 2024
Meet with Modular Medical CEO, Jeb BesserObesity is linked to 30% to 53% of new diabetes cases in the U.S. every year, per research in the Journal of the American Heart AssociationAbout half of all patients prescribed a GLP-1 drug for weight loss discontinued after...
Modular Medical Announces Results from a Successful GLP-1 Proof of Concept Study
-Study showed more potent weight loss and blood glucose control with the addition of a mealtime bolus of a rapid acting GLP-1 to basal delivery- Observed weight loss was 17% at 28 days, a 25% improvement over GLP-1 delivered as basal alone-Findings suggest that pump...
Modular Medical to Present at the Lytham Partners Fall 2024 Investor Conference on October 1
SAN DIEGO, CA / September 30, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" thanks to its...
Modular Medical Announces Issuance of U.S. Patent Covering Key Aspects of Core Pumping Technology
Allowed claims cover major features of pumping mechanism in FDA-cleared MODD1 productSAN DIEGO, CA / September 18, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch...
Modular Medical Announces Finalization of Protocol for GLP-1 Personalized Metabolic Therapy Study Utilizing the MODD1 Platform
-Proof of Concept Study in Rapid Acting GLP-1 to commence in October 2024 with data expected in November 2024-Pre-clinical study to explore use of MODD1 pump as a personalized delivery system for people who discontinue long-acting GLP-1 formulations-CEO to discuss...